Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cutaneous Manifestations of Reactions to Biologics

Cutaneous Manifestations of Reactions to Biologics Purpose of Review The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics. Recent Findings Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. IL-17 inhibitors are unique in increasing risk for Candida infections. Benign injection site reactions, non-specific rash, cellulitis, and hypersensi- tivity reactions are relatively common adverse events. Summary A wide variety of cutaneous reactions caused by biologics have been reported, ranging from benign injection site reactions to life-threatening cutaneous reactions necessitating discontinuation of the implicated biologic agent. . . . . . Keywords Cutaneous reactions Biologics Biological therapies Anti-TNF agents IL-6 inhibitors IL-12/23 inhibitors Abbreviations IL-6 inhibitors TNF Tumor necrosis factor B-cell depletion IBD Inflammatory bowel disease IL-12/23 inhibitors ISRs Injection site reactions IL-17 inhibitors CAPS Cryopyrin-associated periodic syndromes Immune checkpoint inhibitors FMF Familial Mediterranean fever IL-4/13 inhibitors TRAPS TNF receptor-1-associated periodic syndrome IL-5 inhibitors HSRs Hypersensitivity reactions JAK3 inhibitor SLE Systemic lupus erythematosus Costimulation blockade irAEs Immune-related adverse effects Integrin receptor antagonists Summary Introduction TNF-α inhibitors Biological therapies are http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

Cutaneous Manifestations of Reactions to Biologics

Loading next page...
 
/lp/springer-journals/cutaneous-manifestations-of-reactions-to-biologics-ATA0J1b2TK

References (134)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Allergology
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-018-0764-z
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics. Recent Findings Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. IL-17 inhibitors are unique in increasing risk for Candida infections. Benign injection site reactions, non-specific rash, cellulitis, and hypersensi- tivity reactions are relatively common adverse events. Summary A wide variety of cutaneous reactions caused by biologics have been reported, ranging from benign injection site reactions to life-threatening cutaneous reactions necessitating discontinuation of the implicated biologic agent. . . . . . Keywords Cutaneous reactions Biologics Biological therapies Anti-TNF agents IL-6 inhibitors IL-12/23 inhibitors Abbreviations IL-6 inhibitors TNF Tumor necrosis factor B-cell depletion IBD Inflammatory bowel disease IL-12/23 inhibitors ISRs Injection site reactions IL-17 inhibitors CAPS Cryopyrin-associated periodic syndromes Immune checkpoint inhibitors FMF Familial Mediterranean fever IL-4/13 inhibitors TRAPS TNF receptor-1-associated periodic syndrome IL-5 inhibitors HSRs Hypersensitivity reactions JAK3 inhibitor SLE Systemic lupus erythematosus Costimulation blockade irAEs Immune-related adverse effects Integrin receptor antagonists Summary Introduction TNF-α inhibitors Biological therapies are

Journal

Current Allergy and Asthma ReportsSpringer Journals

Published: Feb 21, 2018

There are no references for this article.